- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324869
Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME) (Frontier-1)
An Open-label, Randomized, Uncontrolled, Preliminary Clinical Study to Evaluate the Safety and Efficacy of KH902 Following Multiple Intravitreal Injection in Patients With Diabetic Macular Edema
Study Overview
Detailed Description
With improvement of our living standard, patients who suffered from Diabetes become more and more. As the investigators know, Diabetes can induce many ocular diseases leading to vision loss. And according to observations, DME is diagnosed as one main cause of vision loss in the patients with Diabetes.
As the results of many studies conducted previously, anti-VEGF drugs and anti-VEGF treatments show its effect and safety not only in treating AMD, but also in patients with DME. The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The previous clinical trials of KH902 show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF. Due to these positive results, the investigators prepare to conduct a clinical trial to assess the safety and efficacy with intravitreal injection of KH902 in patients with DME.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200125
- Shanghai First People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed the Informed Consent Form and willing to comply with study procedures;
- 18 years old ≦ either gender ≦ 75 years old;
- Confirmed diagnosed with Type 1 diabetes or Type 2 diabetes based on the diabetes diagnosis criteria;
Clinically significant DME:
- Hard exudation within 500μm of the central foveal diameter accompanied with contiguous retina thickening;
- The edema locates within 500μm of the central foveal diameter;
- Retina thickening field > 1DD and within the 1DD central fovea.
- BCVA score of the study eyes between 78 and 19 letters, inclusively, and the BCVA score of fellow eyes ≥ 24 letters;
- Previous treatment of antidiabetic drugs within three months preceding the screening, and blood-glucose concentration is predicted to be unchanged and stable during the whole study.
Exclusion Criteria:
- Uncontrolled glaucoma in either eye;
- Currently active ocular inflammation or infection in either eye;
- Macular edema in the study eye was caused by other diseases rather than diabetes;
- Company with any other ocular conditions failing to prevent vision loss despite improving the macular edema;
- Any other ocular diseases which may cause macular edema or vision alteration during study phase;
- Retinal macular traction or macular epiretinal membrane in study eye;
- Refractive error equate or exceed 8 diopters of myopia in study eye
- Whole or regional retinal laser photocoagulation has been applied in study eye within 6 months preceding the screening;
- Previous anti-VEGF drug treatment in study eye;
- Intraocular or periocular injection of steroid drug within 6 months preceding the screening;
- Previous ophthalmologic operation within 3 months preceding the screening and/or planning to receive an ophthalmologic operation during the study.
- There is any potential for the study eye to receive the panretinal laser photocoagulation treatment during the study;
- Previous vitrectomy in study eye.
- Uncontrolled diabetes;
- Hypertensive patients with poorly controlled blood pressure;
- Uncontrolled systemic infectious diseases;
- Systemic immune diseases;
- History of allergy;
- Any uncontrolled clinical disorders;
- Pregnant or nursing women;
- Adopt one or more adequate contraception methods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
|
Intravitreal injection of 0.5mg/eye/time KH902
|
Experimental: Group B
Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
|
Intravitreal injection of 0.5mg/eye/time KH902
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of adverse event
Time Frame: up to 12 months
|
To evaluate the safety of multiple intravitreal injection of KH902 to treat DME.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in BCVA
Time Frame: at the end of month 3 and the end of month 12
|
To evaluate the efficacy of multiple intravitreal injection of KH902 of each group.
|
at the end of month 3 and the end of month 12
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xun Xu, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Study Director: Lun De Luo, Chengdu Kanghong Biotech Co., Ltd.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KHSWKH902002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on KH902
-
Chengdu Kanghong Biotech Co., Ltd.University of Wisconsin, Madison; Air Force Military Medical University, ChinaCompletedNeovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityRecruiting
-
Chengdu Kanghong Biotech Co., Ltd.Beijing DMS Pharma Ltd.; The Digital Angiography Reading Center (DARC)CompletedNeovascular Age-related Macular DegenerationChina